| Literature DB >> 30367915 |
Seung Ah Choi1, Chanhee Lee1, Pil Ae Kwak1, Chul-Kee Park2, Kyu-Chang Wang3, Ji Hoon Phi1, Ji Yeoun Lee4, Sangjoon Chong1, Seung-Ki Kim5.
Abstract
Human adipose tissue-derived mesenchymal stem cells expressing the secreted form of the tumor necrosis factor-related apoptosis-inducing ligand (hAT-MSC.sTRAIL) have demonstrated therapeutic activity against various tumors in preclinical studies. However, the limited expression of TRAIL death receptors remains a challenge. We evaluated the therapeutic efficacy of panobinostat in enhancing the sensitivity of hAT-MSC.sTRAIL-mediated apoptosis in malignant glioma. Panobinostat effectively inhibited all malignant glioma cells (IC50, 0.03-0.23 μM), enhancing the expression of DRs, but not in hAT-MSCs. Combined treatment with hAT-MSC.sTRAIL and panobinostat significantly suppressed cell viability and enhanced apoptosis. In a diffuse intrinsic pontine glioma (DIPG) mouse model, the combined treatment induced decreases in tumor volume and prolonged survival. Our study demonstrates that panobinostat enhances the expression of TRAIL DRs and potentiates the anti-cancer effects of hAT-MSC.sTRAIL.Entities:
Keywords: Antitumor effect; Apoptosis; Malignant glioma; Panobinostat; hAT-MSC.sTRAIL
Mesh：
Substances：
Year: 2018 PMID： 30367915 DOI： 10.1016/j.canlet.2018.10.012
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679